Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Type 1 Diabetes With Diabetic Macular Edema, Type 2 Diabetes With Diabetic Macular Edema
Conditions
Keywords
Diabetic Macular Edema, Macular Edema, Center-involved Diabetic Macular Edema, Center-involved DME, DME, Diabetic Retinopathy
Brief summary
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.
Interventions
DRUGMS-553
MS-553
Sponsors
Fountain Medical Development Co., Ltd.
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of diabetes mellitus (type 1 or type 2) according to ADA or WHO diabetic diagnosis criteria * Subject has the ability to follow the study instructions and is likely to complete all required study procedures and visits; * All males and females must consent to pregnancy prevention during the study and qualified measures of birth control. All females of childbearing potential must consent to a pregnancy test before entering the study. * Presence of central involved macular edema associated with diabetic retinopathy, i.e. diabetic macular edema (DME), as assessed by spectral domain optical coherence tomography (sd-OCT) of the central retina subfield thickness (CRT) at the Screening Visit (Centration must be confirmed by Investigators with signatures); * Best Corrected Visual Acuity (BCVA) score ≥ 34 letters (approximately 20/200 to 20/20 Snellen equivalent or better) using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity protocol, and assessed at the Screening Visit Visual acuity (VA); * Confirmation by the investigator that laser photocoagulation and anti-VEGF treatments are either declined by the patients or not needed and can be withheld for at least 3 months after the Screening Visit; * Ocular media and pupil dilation adequate to permit good quality retinal imaging as assessed at Screening Visit.
Exclusion criteria
* Subjects with unstable metabolic or blood pressure control * Subject with emaciation or obesity at Screening Visit: body mass index (BMI) \<18.5kg/m2 or \>28kg/m2 * Current use or likely need for medications know to be toxic to the lens, retina or optic nerve, including Deferoxamine, Chloroquine / hydroxychloroquine (Plaquenil), Tamoxifen, Phenothiazines and Ethambutol - * History of myocardial infarction or other cardiac event requiring hospitalization (unstable angina pectoris, etc.), cerebrovascular accident, transient ischemic attack, treatment for acute congestive heart failure or any arrhythmia within 4-months prior to Screening Visit; * Any situation that may in the opinion of the investigator preclude the safe administration of the study medication, adherence to the scheduled study visits, safe participation in the study or affect the results of the study as assessed at Screening Visit;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment-emergent adverse events | Baseline to Day 56 |
Secondary
| Measure | Time frame |
|---|---|
| Mean change in the central retina subfield thickness (CRT) | Baseline to Day 56 |
| Mean change in the retinal volume | Baseline to Day 56 |
| Proportion of patients with >20% reduction in CRT | Baseline to Day 56 |
| Proportion of patients with resolution of central involved macular edema | Baseline to Day 56 |
| Average mean change in best corrected visual acuity | Baseline to Day 56 |
Countries
China
Contacts
Primary ContactLing Yang
Outcome results
None listed